Effect of Tacrolimus with Mycophenolate Mofetil or Cyclophosphamide on Renal Response in Lupus Patients
Author Information
Author(s): Sun Siqin, Zhang Xueyi, Guo Qingqing, Tang Xiaojun, Shen Wei, Liang Jun, Yao Genhong, Geng Linyu, Ding Shuai, Chen Hongwei, Wang Hong, Hua Bingzhu, Zhang Huayong, Feng Xuebing, Jin Ziyi, Sun Lingyun
Primary Institution: Nanjing Drum Tower Hospital, Nanjing University Medical School
Hypothesis
This study aimed to determine the therapeutic efficacy of tacrolimus (TAC) with mycophenolate mofetil (MMF) or cyclophosphamide (CYC) on the renal response in systemic lupus erythematosus (SLE) patients.
Conclusion
Tacrolimus can effectively alleviate the condition of patients with SLE and may interact with MMF or CYC, suggesting that the combination therapy may produce greater benefits.
Supporting Evidence
- 27.9% of SLE patients achieved complete response after at least 3 months.
- TAC use was positively associated with complete response with an adjusted odds ratio of 2.82.
- A dose-response effect on complete response was observed at TAC doses greater than 4 mg/d.
Takeaway
This study found that using a medicine called tacrolimus can help kids and adults with a disease called lupus feel better, especially when it's used with other medicines.
Methodology
A retrospective cohort study based on medical data was conducted among SLE patients who took TAC, MMF, or CYC from 2010 to 2021.
Potential Biases
The study may have biases due to its retrospective nature and reliance on medical records.
Limitations
This was a retrospective observational study with potential confounding factors and limited renal biopsy data.
Participant Demographics
The study included 793 SLE patients, with a median age of 37 years for non-users and 27 years for users of TAC.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 1.89, 4.22
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website